Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 11/20 | 0.50 |
| ▸ | BCHE | P06276 | 5/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.45 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CCR6 | P51684 | 1/20 | 0.41 |
| ▸ | CFTR | P13569 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14768751 | 0.86 | TP53 (0.47) | ACHEBCHENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10062380 | 0.74 | KDM5A (0.70) | ACHEBCHEGAAHTTTDP1 | |
| SCHEMBL28768806 | 0.65 | SMN1; SMN2 (0.55) | NPC1RAB9ASMN1; SMN2GAAHTT | |
| SCHEMBL12043409 | 0.64 | ACHE (1.00) | ACHEBCHEGRIN1GRIN2AAPP | |
| SCHEMBL9926442 | 0.64 | BCHE (1.00) | ACHEBCHEAPPNPC1 | |
| SCHEMBL3798774 | 0.64 | HTT (0.55) | ACHEBCHEGAAHTT | |
| SCHEMBL16729242 | 0.63 | NPC1 (0.52) | NPC1RAB9ASMN1; SMN2HTT | |
| SCHEMBL9749208 | 0.61 | HTT (0.64) | ACHEBCHENPC1RAB9AGAA | |
| SCHEMBL1147798 | 0.61 | NPC1 (0.44) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29352418 | 0.60 | SMN1; SMN2 (0.62) | NPC1RAB9ASMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9464064-B2 | HCV helicase inhibitors and methods of use thereof | UNIVERSITY OF KANSAS (US) | 2016-10-11 | — | — | US | disclosed |
| US-20140227225-A1 | HCV Helicase Inhibitors and Methods of Use Thereof | UWM RESEARCH FOUNDATION, INC. (US) | 2014-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140227225-A1 | HCV Helicase Inhibitors and Methods of Use Thereof | DHX15, DDX5, DHX35 | ACHE 688/4885BCHE 666/4885GRIN1 4740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.